person · Reporting owner
Friedl-Naderer Johanna
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dyne Therapeutics, Inc.DYN · Entity 3948 | Chief Commercial Officer | September 04, 2026 | September 08, 2026 |
| Vir Biotechnology, Inc.VIR · Entity 4522 | EVP & Chief Operating Officer | March 03, 2023 | March 07, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dyne Therapeutics, Inc.
Report date September 04, 2026 · Filed September 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 153,082 |
Reported balance
After 2026-09-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-04 · Sale · Disposed 900 · Balance 153,082 F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 3, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $24.29 to $24.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 152,897 |
Reported balance
After 2026-09-08 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-08 · Sale · Disposed 185 · Balance 152,897 F3: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.77 to $18.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F5: Includes 102,966 unvested RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 3, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $24.29 to $24.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
F3: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.77 to $18.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
F5: Includes 102,966 unvested RSUs.
Vir Biotechnology, Inc.
Report date March 03, 2023 · Filed March 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 148,518 |
Reported balance
After 2023-03-03 transaction · row 1
1 source rowRow 1 · 2023-03-03 · Sale · Disposed 1,482 · Balance 148,518 F1: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2026 Filed Sep 8, 2026 20:15 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 185 | $18.88 | $3,492.80 |
DisclosureSEC source: 0001915598-26-000005 · ownership.xml · nonDerivative · entry 2 Friedl-Naderer Johanna · CIK 0001915598 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 152,897 F3 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.77 to $18.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F5 · balance_after: Includes 102,966 unvested RSUs. Read SEC document |
| September 04, 2026 Filed Sep 8, 2026 20:15 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 900 | $24.35 | $21,915.00 |
DisclosureSEC source: 0001915598-26-000005 · ownership.xml · nonDerivative · entry 1 Friedl-Naderer Johanna · CIK 0001915598 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,082 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 3, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $24.29 to $24.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. Read SEC document |
| August 13, 2026 Filed Aug 17, 2026 20:08 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 226 | $26.28 | $5,939.28 |
DisclosureSEC source: 0001915598-26-000004 · ownership.xml · nonDerivative · entry 1 Friedl-Naderer Johanna · CIK 0001915598 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,982 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.17 to $26.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 119,928 unvested RSUs. Read SEC document |
| June 16, 2026 Filed Jun 17, 2026 20:07 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 145 | $18.33 | $2,657.85 |
DisclosureSEC source: 0001915598-26-000002 · ownership.xml · nonDerivative · entry 1 Friedl-Naderer Johanna · CIK 0001915598 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,208 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.01 to $18.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 123,678 unvested RSUs. Read SEC document |
| May 13, 2026 Filed May 14, 2026 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 228 | $18.36 | $4,186.08 |
DisclosureSEC source: 0001193125-26-223984 · ownership.xml · nonDerivative · entry 1 Friedl-Naderer Johanna · CIK 0001915598 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,353 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.20 to $18.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 126,040 unvested RSUs. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 21:10 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 148 | $14.90 | $2,205.20 |
DisclosureSEC source: 0001193125-26-096523 · ownership.xml · nonDerivative · entry 1 Friedl-Naderer Johanna · CIK 0001915598 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,581 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 129,790 unvested RSUs. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 22:09 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock option (right to buy) · Derivative | 90,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-055063 · ownership.xml · derivative · entry 2 Friedl-Naderer Johanna · CIK 0001915598 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2036-02-11 F3 · derivative.exercise_date: This option was granted on February 12, 2026. The shares underlying the option are scheduled to vest over four years in equal monthly installments through February 12, 2030. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 22:09 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-055063 · ownership.xml · nonDerivative · entry 1 Friedl-Naderer Johanna · CIK 0001915598 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,729 F1 · shares: Consists of shares of Common Stock issuable under 60,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on May 12, 2026. F2 · balance_after: Includes 132,152 unvested RSUs. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 21:08 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 144 | $20.72 | $2,983.68 |
DisclosureSEC source: 0001193125-25-309636 · ownership.xml · nonDerivative · entry 1 Friedl-Naderer Johanna · CIK 0001915598 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,729 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.58 to $20.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 72,152 unvested RSUs. Read SEC document |
| September 05, 2025 Filed Sep 8, 2025 20:06 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 144 | $13.41 | $1,931.04 |
DisclosureSEC source: 0000950170-25-113545 · ownership.xml · nonDerivative · entry 2 Friedl-Naderer Johanna · CIK 0001915598 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,873 F3 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F4 · balance_after: Includes 74,514 unvested RSUs. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 20:06 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 894 | $13.27 | $11,863.38 |
DisclosureSEC source: 0000950170-25-113545 · ownership.xml · nonDerivative · entry 1 Friedl-Naderer Johanna · CIK 0001915598 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,017 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 3, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.08 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 21:21 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock option (right to buy) · Derivative | 51,255 | $0.00 Strike: $9.33 | $0.00 |
DisclosureSEC source: 0000950170-25-097007 · ownership.xml · derivative · entry 1 Friedl-Naderer Johanna · CIK 0001915598 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,255 Underlying: Common Stock · 51,255 shares Expires 2035-07-15 F1 · derivative.exercise_date: This option was granted on July 16, 2025 (the "Grant Date"). The shares underlying the option are scheduled to vest over three years, with 50% of the shares underlying the grant vesting 18 months after the Grant Date and with the balance of the shares underlying the grant vesting in equal quarterly installments thereafter; provided that such option shall not be exercisable unless and until (i) the average closing price of the common stock on the Nasdaq Global Select Market over a 20 consecutive trading day period equals or exceeds $20.00 per share at any time during the three-year period following the Grant Date (the "Performance Period") or (ii) a Change in Control (as defined in the Issuer's Amended and Restated Executive Severance and Change in Control Benefits Plan) is consummated during the Performance Period pursuant to which a third party acquires the common stock for a price per share that the Board of Directors of the Issuer determines equals or exceeds $20.00 per share. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 20:03 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 146 | $13.35 | $1,949.10 |
DisclosureSEC source: 0000950170-25-083033 · ownership.xml · nonDerivative · entry 1 Friedl-Naderer Johanna · CIK 0001915598 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,911 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.21 to $13.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 91,476 unvested RSUs. Read SEC document |
| March 13, 2025 Filed Mar 13, 2025 20:13 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 143 | $12.12 | $1,733.16 |
DisclosureSEC source: 0000950170-25-038750 · ownership.xml · nonDerivative · entry 1 Friedl-Naderer Johanna · CIK 0001915598 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,057 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 93,838 unvested RSUs. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 21:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock option (right to buy) · Derivative | 60,300 | $0.00 Strike: $29.44 | $0.00 |
DisclosureSEC source: 0000950170-24-134078 · ownership.xml · derivative · entry 2 Friedl-Naderer Johanna · CIK 0001915598 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,300 Underlying: Common Stock · 60,300 shares Expires 2034-12-03 F3 · derivative.exercise_date: This option was granted on December 4, 2024. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 4, 2028. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 21:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantCommon Stock | 37,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-134078 · ownership.xml · nonDerivative · entry 1 Friedl-Naderer Johanna · CIK 0001915598 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,200 F1 · shares: Consists of shares of Common Stock issuable under 37,800 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 4, 2025. F2 · balance_after: Includes 96,200 unvested RSUs. Read SEC document |
| September 03, 2024 Filed Sep 3, 2024 22:16 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock Option (Right to Buy) · Derivative | 185,300 | $0.00 Strike: $31.94 | $0.00 |
DisclosureSEC source: 0000950170-24-103033 · ownership.xml · derivative · entry 2 Friedl-Naderer Johanna · CIK 0001915598 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,300 Underlying: Common Stock · 185,300 shares Expires 2034-09-02 F2 · derivative.exercise_date: This option was granted on September 3, 2024. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on September 3, 2025, and the remainder vesting in equal quarterly installments thereafter, subject to continuous service. Read SEC document |
| September 03, 2024 Filed Sep 3, 2024 22:16 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantCommon Stock | 58,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-103033 · ownership.xml · nonDerivative · entry 1 Friedl-Naderer Johanna · CIK 0001915598 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,400 F1 · shares: Consists of shares of Common Stock issuable under 58,400 restricted stock units ("RSU"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on September 3, 2025. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 19:04 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,482 | $22.82 | $33,819.24 |
DisclosureSEC source: 0001209191-23-016629 · doc4.xml · nonDerivative · entry 1 Friedl-Naderer Johanna · CIK 0001915598 · EVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,518 F1 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 01:27 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $27.01 | $0.00 |
DisclosureSEC source: 0001209191-23-012991 · doc4.xml · derivative · entry 2 Friedl-Naderer Johanna · CIK 0001915598 · EVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2033-02-21 F2 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on February 22, 2024, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 01:27 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-012991 · doc4.xml · nonDerivative · entry 1 Friedl-Naderer Johanna · CIK 0001915598 · EVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
| March 02, 2022 Filed Mar 8, 2022 16:35 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $24.13 | $0.00 |
DisclosureSEC source: 0001209191-22-016929 · doc4.xml · derivative · entry 2 Friedl-Naderer Johanna · CIK 0001915598 · Chief Business Officer, Global 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2032-03-01 F2 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on March 2, 2023, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
| March 02, 2022 Filed Mar 8, 2022 16:35 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016929 · doc4.xml · nonDerivative · entry 1 Friedl-Naderer Johanna · CIK 0001915598 · Chief Business Officer, Global 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.